NICE shoots down Dupixent for severe asthma
pharmafile | March 9, 2020 | News story | Sales and Marketing | Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma
NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 inhibitor Dupixent (dupilumab) in the treatment of severe asthma.
The indication specifically relates to patients with type 2 inflammation that does not respond adequately to the combination of high-dose inhaled corticosteroids and another maintenance therapy.
The decision was made despite data indicating the superiority of Dupixent, when combined with standard asthma treatment, compared to placebo in reducing exacerbation frequency and reliance on oral corticosteroids in this patient population.
Ultimately, this was due to cost estimates for use of the drug coming in at a level higher than NHS resources would support.
Patients in this target population often prove difficult to treat and are prone to hospitalisation when sudden exacerbations arise.
Matt Fellows
Related Content
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
Sanofi shares phase 2b results for dermatitis treatment
Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …
GSK’s Jemperli recommended by NICE for endometrial cancer treatment
GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended …